- Home
- DMAC vs GGT Comparison
DMAC vs GGT Comparison
Compare DMAC & GGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- GGT
- Stock Information
- Founded
- DMAC 2000
- GGT 1994
- Country
- DMAC United States
- GGT United States
- Employees
- DMAC N/A
- GGT N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- GGT Trusts Except Educational Religious and Charitable
- Sector
- DMAC Health Care
- GGT Finance
- Exchange
- DMAC Nasdaq
- GGT Nasdaq
- Market Cap
- DMAC 158.1M
- GGT 128.7M
- IPO Year
- DMAC N/A
- GGT N/A
- Fundamental
- Price
- DMAC $4.11
- GGT $4.02
- Analyst Decision
- DMAC Strong Buy
- GGT
- Analyst Count
- DMAC 2
- GGT 0
- Target Price
- DMAC $8.00
- GGT N/A
- AVG Volume (30 Days)
- DMAC 102.4K
- GGT 59.7K
- Earning Date
- DMAC 05-13-2025
- GGT 01-01-0001
- Dividend Yield
- DMAC N/A
- GGT 15.56%
- EPS Growth
- DMAC N/A
- GGT N/A
- EPS
- DMAC N/A
- GGT 0.83
- Revenue
- DMAC N/A
- GGT N/A
- Revenue This Year
- DMAC N/A
- GGT N/A
- Revenue Next Year
- DMAC N/A
- GGT N/A
- P/E Ratio
- DMAC N/A
- GGT $6.90
- Revenue Growth
- DMAC N/A
- GGT N/A
- 52 Week Low
- DMAC $2.14
- GGT $4.32
- 52 Week High
- DMAC $6.82
- GGT $7.00
- Technical
- Relative Strength Index (RSI)
- DMAC 50.90
- GGT 26.83
- Support Level
- DMAC $3.92
- GGT $4.07
- Resistance Level
- DMAC $4.33
- GGT $4.16
- Average True Range (ATR)
- DMAC 0.29
- GGT 0.08
- MACD
- DMAC 0.02
- GGT -0.01
- Stochastic Oscillator
- DMAC 56.79
- GGT 9.30
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.